Latest & greatest articles for amlodipine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amlodipine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amlodipine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amlodipine

1. Efficacy of amlodipine besylate and valsartan (ABVS) for the treatment of mild to moderate hypertension (MMH): a systematic review

Efficacy of amlodipine besylate and valsartan (ABVS) for the treatment of mild to moderate hypertension (MMH): a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

2. Amlodipine

Amlodipine Top results for amlodipine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for amlodipine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Efficacy of isoproterenol for treating amlodipine overdose resulting in bradycardia (PubMed)

Efficacy of isoproterenol for treating amlodipine overdose resulting in bradycardia Amlodipine predominantly affects vascular smooth muscle cells. Amlodipine overdose usually presents with vasodilatory shock, accompanied by reflex tachycardia rather than bradycardia.An 81-year-old woman presented with impaired consciousness 8 h after ingesting 50 5-mg amlodipine tablets with suicidal intent. On admission, her blood pressure was 50/40 mmHg and her heart rate was 45 b.p.m. Serum amlodipine level (...) complications.Isoproterenol is effective for treating bradycardia after amlodipine overdose.

Full Text available with Trip Pro

2017 Acute medicine & surgery

4. Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study (PubMed)

Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study EXCITE (clinical experience of amlodipine and valsartan in hypertension) evaluated the real-world effectiveness and safety of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from the Middle East and Asia.The objective of this study

Full Text available with Trip Pro

2016 Drugs - real world outcomes

5. perindopril arginine / amlodipine (Viacoram)

perindopril arginine / amlodipine (Viacoram) perindopril arginine / amlodipine | CADTH.ca Find the information you need perindopril arginine / amlodipine perindopril arginine / amlodipine Last Updated: April 4, 2016 Result type: Reports Project Number: SR0490-000 Product Line: Generic Name: perindopril arginine / amlodipine Brand Name: Viacoram Manufacturer: Servier Canada Inc. Indications: Hypertension, essential Submission Type: New Project Status: Complete Date Recommendation Issued: October

2016 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

6. Amlodipine / Valsartan Mylan - hypertension

Amlodipine / Valsartan Mylan - hypertension 28 January 2016 EMA/CHMP/182030/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Amlodipine/Valsartan Mylan International non-proprietary name: amlodipine / valsartan Procedure No. EMEA/H/C/004037/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone (...) /National Formulary UV Ultraviolet light Assessment report EMA/CHMP/182030/2016 Page 4/31 1. Background information on the procedure 1.1. Submission of the dossier The applicant MYLAN S.A.S. submitted on 20 January 2015 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Amlodipine/Valsartan Mylan, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004 – ‘Generic of a Centrally authorised product’. The eligibility to the centralised

2016 European Medicines Agency - EPARs

7. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud`s phenomenon: a double-blind, randomized, cross-over study (PubMed)

Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud`s phenomenon: a double-blind, randomized, cross-over study RP is a reversible vasoconstriction of digital arteries that causes pain and skin discoloration. This study compared the efficacy of the new phosphodiesterase type 5 inhibitor udenafil with that of the calcium channel blocker amlodipine in the treatment of secondary RP.A total of 29 patients with secondary RP associated with connective tissue (...) diseases were enrolled in this double-blind, randomized, cross-over study. The patients were randomized to receive udenafil 100 mg/day or amlodipine 10 mg/day for 4 weeks. After a washout period they were crossed over to the other drug for another 4 weeks. The primary outcome was RP frequency before and after treatment. The secondary outcomes were RP condition scores, RP duration, number of digital ulcers, HAQ, physician global assessment and digital artery flow before and after treatment.Amlodipine

Full Text available with Trip Pro

2014 EvidenceUpdates

8. [Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

[Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Aliskiren / Amlodipin – Nutzenbewertung gemäß § 35a SGB V [Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Aliskiren / Amlodipin – Nutzenbewertung gemäß § 35a SGB V [Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social (...) Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Aliskiren / Amlodipin – Nutzenbewertung gemäß § 35a SGB V. [Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und

2012 Health Technology Assessment (HTA) Database.

9. Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial (PubMed)

Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial To assess the extent of reduction in blood pressure (BP) of aliskiren/amlodipine combination therapy compared with amlodipine monotherapy in moderate-to-severe hypertensive patients.This was an 8-week multicentre, randomised, double-blind study. After a 1-to 4-week washout period, eligible patients [mean sitting systolic blood pressure (msSBP (...) ) ≥ 160 to < 200 mmHg] were randomised to receive a once-daily dose of aliskiren/amlodipine 150/5mg (n = 244) or amlodipine 5 mg (n = 241) for 1 week, followed by up-titration to aliskiren/amlodipine 300/10 mg or amlodipine 10 mg for 7 weeks. Efficacy outcome measures included change from baseline to week 8 endpoint in msSBP (primary endpoint), mean sitting diastolic blood pressure (msDBP), and BP control rate (< 140/90 mmHg). Safety was assessed by monitoring and recording all adverse events (AEs

2012 EvidenceUpdates

10. A 48-week study of amlodipine plus amiloride / hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension (PubMed)

A 48-week study of amlodipine plus amiloride / hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension Background:  Chinese Hypertension Intervention Efficacy (CHIEF) study is a large-scale randomised clinical trial across China, which compares the efficacy of two combination regimens in reducing cardiovascular events associated with hypertension. Methods:  We reported the 48-week efficacy and tolerability of the two antihypertensive regimens in participants from (...) Shandong Province, China. Eligible patients aged 50-79 years were randomised to receive amlodipine plus amiloride/hydrochlorothiazide (Group A) or amlodipine plus telmisartan (Group B). The doses of both regimens were titrated and other antihypertensive agents were added subsequently to achieve a blood pressure (BP) goal (<140/90 mmHg for general population, <130/80 mmHg for diabetics and <150/90 mmHg for elderly). Efficacy variables included the changes of BP, control rates (the proportion of patients

2012 EvidenceUpdates

11. Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials

Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

12. Aliskiren / amlodipine - Benefit assessment according to § 35a Social Code Book V

Aliskiren / amlodipine - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment (“Aliskiren/Amlodipin – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status10.02.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports - Commission No. A11-29 Aliskiren / amlodipine – Benefit (...) assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A11-29 Version 1.0 Aliskiren / amlodipine - Benefit assessment acc. to § 35a Social Code Book V 10.02.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Aliskiren /amlodipine - Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded on: 14.11.2011

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

13. Simvastatin: dose limitations with concomitant amlodipine or diltiazem

Simvastatin: dose limitations with concomitant amlodipine or diltiazem Simvastatin: dose limitations with concomitant amlodipine or diltiazem - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Simvastatin: dose limitations with concomitant amlodipine or diltiazem The maximum recommended dose for simvastatin in conjunction with amlodipine and diltiazem is now 20 mg/day. Published 11 December 2014 From: Therapeutic area: , Contents Article date: October 2012 Pharmacokinetic data (...) Simvastatin is metabolised through the CYP3A4 pathway. Concomitant use of CYP3A4 inhibitors has the potential to increase exposure to simvastatin . Both amlodipine and diltiazem are substrates and inhibitors of CYP3A4 and therefore increase the plasma concentration (AUC0-24h) and maximum plasma concentration (Cmax) of simvastatin when they are co-administered. Studies have found that after 10 days of amlodipine (10 mg), the AUC0-24h of simvastatin and simvastatic acid following a single dose

2012 MHRA Drug Safety Update

14. Telmisartan / Amlodipine - Essential Hypertension

Telmisartan / Amlodipine - Essential Hypertension Common Drug Review CDEC Meeting – November 16, 2011 Page 1 of 3 Notice of CDEC Final Recommendation – December 16, 2011 © 2011 CADTH CDEC FINAL RECOMMENDATION TELMISARTAN/AMLODIPINE (Twynsta – Boehringer Ingelheim Canada Ltd.) Indication: Essential Hypertension Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that telmisartan/amlodipine fixed- dose combination (FDC) (Twynsta) be listed. Reasons for the Recommendation: 1 (...) . Telmisartan/amlodipine FDC, at both the lowest and highest recommended doses, was demonstrated to be bioequivalent to the same doses of its individual components given separately. 2. At the submitted price, the cost of telmisartan/amlodipine FDC ($0.68 daily) is less than telmisartan ($1.13 daily) plus amlodipine ($0.34 to $0.50 daily) given separately. Of Note: The Committee gave consideration to the provision in the Health Canada product monograph which states that telmisartan/amlodipine FDC

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

15. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. (PubMed)

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control (...) by monotherapy impairs subsequent control by combination therapy.We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo

2011 Lancet

16. Randomised controlled trial: Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy

Randomised controlled trial: Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your (...) and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy Article Text Therapeutics Randomised controlled trial Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapy John M Flack 1 , Samar A Nasser 1 , Phillip D Levy 2 Statistics from Altmetric.com Commentary on: Brown MJ , McInnes GT , Papst CC , et al . Aliskiren and the calcium channel blocker amlodipine

2011 Evidence-Based Medicine (Requires free registration)

17. Rasilamlo - aliskiren / amlodipine

Rasilamlo - aliskiren / amlodipine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report for Rasilamlo International Nonproprietary Name: aliskiren / amlodipine Procedure No. EMEA/H/C/002073 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Medicinal product (...) requested the relevant documentation as follow-up measure. The results from these additional studies were not considered required by the Committee before the adoption of the positive CHMP opinion and it is confirmed that these applications comply with Article 6 of Regulation 726/2004 having regard to the requirements of Article 8(3) (ca) of Directive 2001/83. 2.3.6. Discussion on non-clinical aspects No specific studies with the aliskiren/amlodipine fixed combination have been conducted concerning

2011 European Medicines Agency - EPARs

18. Rasitrio - aliskiren / amlodipine / hydrochlorothiazide

Rasitrio - aliskiren / amlodipine / hydrochlorothiazide 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report for Rasitrio International non-proprietary name: aliskiren / amlodipine / hydrochlorothiazide Procedure No. EMEA/H/C/002017 Assessment Report as adopted by the CHMP with all information of a commercially (...) radioisotope ABPM ambulatory blood pressure monitoring ACE Angiotensin converting enzyme ACE angiotensin-converting enzyme ADME Absorption, distribution, metabolism and excretion ADR adverse drug reaction AE adverse event Al Aluminium Ali aliskiren ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Aml amlodipine Ang angiotensin AR1 Autoregressive order 1 ARB Angiotensin receptor blocker ARB angiotensin receptor blocker ATR Attenuated Total Reflection AUC area under

2011 European Medicines Agency - EPARs

19. Onduarp - telmisartan / amlodipine

Onduarp - telmisartan / amlodipine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. 22 September 2011 EMA/891763/2011 Committee for Medicinal Products for Human Use (CHMP) Assessment report Onduarp International non-proprietary name (...) : telmisartan / amlodipine Procedure No. EMEA/H/C/002118 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Medicinal product no longer authorisedTable of contents 1. Background information on the procedure 4 1.1 Submission of the dossier 4 Information on Paediatric requirements 4 Information relating to orphan market exclusivity 4 Scientific Advice 4 Licensing status 4 1.2 Steps taken for the assessment of the product 5 2. Scientific discussion 6 2.1

2011 European Medicines Agency - EPARs

20. Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study (PubMed)

Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study A majority of hypertensive patients require > or = 2 agents to achieve target blood pressure (BP).This 52-week, multicentre, open-label, randomised extension trial to a previously reported double-blind, placebo-controlled study evaluated the safety and efficacy of amlodipine/valsartan (Aml/Val) combination. Patients who successfully completed the core study without serious

2010 EvidenceUpdates